$311 Million is the total value of Foresite Capital Management IV, LLC's 8 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | $115,576,000 | -5.2% | 9,671,643 | 0.0% | 37.17% | +13.2% | |
| LYEL | Sell | Lyell Immunopharma, Inc. | $73,300,000 | -15.4% | 10,000,000 | -24.7% | 23.57% | +1.1% |
| ACRS | Aclaris Therapeutics, Inc. | $44,198,000 | +12.8% | 2,808,034 | 0.0% | 14.21% | +34.7% | |
| KURA | Kura Oncology, Inc. | $25,270,000 | -25.5% | 1,849,947 | 0.0% | 8.13% | -11.0% | |
| PHVS | Pharvaris N.V. | $24,904,000 | -65.3% | 3,246,926 | 0.0% | 8.01% | -58.5% | |
| SNDX | New | Syndax Pharmaceuticals, Inc. | $16,581,000 | – | 690,000 | +100.0% | 5.33% | – |
| CBAY | Cymabay Therapeutics, Inc. | $6,255,000 | +18.6% | 1,787,094 | 0.0% | 2.01% | +41.7% | |
| QSI | Quantum-Si Incorporated | $4,871,000 | +18.5% | 1,771,249 | 0.0% | 1.57% | +41.6% | |
| NRIX | Exit | Nurix Therapeutics, Inc. | $0 | – | -677,143 | -100.0% | -2.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.